<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pericardial disease associated with cancer: Clinical presentation and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pericardial disease associated with cancer: Clinical presentation and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pericardial disease associated with cancer: Clinical presentation and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry A Borlaug, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Malcolm M DeCamp, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin M LeWinter, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cancer commonly involves the pericardium, with clinical presentations ranging from acute syndromes to indolent conditions.
        </p>
        <p>
         The clinical presentation and diagnosis of pericardial disease associated with cancer is reviewed here. The management of pericardial disease associated with cancer is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/141940.html" rel="external">
          "Pericardial disease associated with cancer: Management"
         </a>
         .)
        </p>
        <p>
         The etiology of pericardial disease and the diagnosis of pericardial effusion, cardiac tamponade, and constrictive pericarditis in the general population are also presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">
          "Etiology of pericardial disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2458438364">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial disease in patients with cancer
         </strong>
         — Pericardial disease occurs in approximately 10 to 20 percent of patients with cancer [
         <a href="#rid1">
          1,2
         </a>
         ]. The frequency of pericardial disease caused by cancer and other conditions varies depending upon the type of cancer and associated complications. (See
         <a class="local">
          'Etiology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In autopsy series of patients with cancer, cardiac or pericardial involvement has been reported in approximately 10 percent of cases [
         <a href="#rid1">
          1,3-5
         </a>
         ]. Of these cases, the epicardium/pericardium was the most common cardiac site of involvement (76 percent), followed by the myocardium (38 percent) and endocardium (16 percent) [
         <a href="#rid2">
          2,3,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer in patients with pericardial disease
         </strong>
         — Acute pericarditis and/or pericardial effusion is associated with an elevated risk of subsequent cancer diagnosis, particularly during the first three months after identification of pericardial disease. In a population-based matched cohort study from the United Kingdom, the incidence of cancer detection was higher among 2221 patients diagnosed with a pericardial effusion than among 11,538 patients diagnosed with acute pericarditis without pericardial effusion (hazard ratio [HR] 3.59, 95% CI 3.18-4.06 versus HR 2.04, 95% CI 1.69-2.46) [
         <a href="#rid7">
          7
         </a>
         ]. Patients with pericardial effusion or acute pericarditis and need for hospitalization, older age, obesity, and/or current smoking had the highest absolute excess risks of cancer identified 3 to 12 months after diagnosis of pericardial disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients who present with pericardial disease, the likelihood of identifying a previously undiagnosed cancer is higher among patients who present with a moderate or large pericardial effusion  (
         <a class="graphic graphic_table graphicRef78847" href="/z/d/graphic/78847.html" rel="external">
          table 1
         </a>
         ), cardiac tamponade [
         <a href="#rid8">
          8,9
         </a>
         ], or effusive-constrictive pericarditis than in those who present with acute pericarditis, a small pericardial effusion, or constrictive pericarditis. These clinical syndromes are discussed below. (See
         <a class="local">
          'Clinical presentation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3827064722">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical conditions that cause pericardial disease in patients with cancer include [
         <a href="#rid8">
          8,10,11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignancy
         </strong>
         (see
         <a class="local">
          'Malignancy'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer therapy
         </strong>
         (eg, radiation therapy [RT], antineoplastic agents) (see
         <a class="local">
          'Cancer therapy'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         (see
         <a class="local">
          'Infection'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic pericarditis
         </strong>
         (see
         <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">
          "Etiology of pericardial disease", section on 'Idiopathic'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Further details on other etiologies of pericardial disease in the general population are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">
          "Etiology of pericardial disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3182770496">
         <span class="h2">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignancy (local invasion, metastases, or mediastinal lymphatic obstruction) is a common cause of pericardial disease in patients with cancer. In observational studies in patients with cancer and pericardial effusion undergoing pericardiocentesis, the frequency of a malignant effusion is approximately 40 to 60 percent [
         <a href="#rid1">
          1,12-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2757700531">
         <span class="h3">
          Metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant tumors can involve the pericardium either by direct local invasion or metastatic spread via the lymphatics or bloodstream. Metastatic disease of the pericardium most commonly presents with pericardial effusion (with or without cardiac tamponade). Metastatic disease less commonly presents as constrictive pericarditis, which is a rare initial manifestation of cancer [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Lung cancer is the most common malignancy to involve the pericardium. In particular, patients with non-small cell lung cancer that harbors an anaplastic lymphoma kinase (ALK) rearrangement are particularly likely to present with a pericardial effusion or other pericardial involvement [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4621.html" rel="external">
          "Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Clinicopathologic features'
         </a>
         .)
        </p>
        <p>
         Other common cancers that can cause pericardial disease include breast and esophageal cancer, melanoma, lymphoma, and leukemia [
         <a href="#rid3">
          3,4,12,13,18-20
         </a>
         ]. Although acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) was previously an important cause of malignant pericardial disease [
         <a href="#rid21">
          21,22
         </a>
         ], the incidence of KS has declined dramatically with widespread use of potent combination antiretroviral therapy. (See
         <a class="medical medical_review" href="/z/d/html/8033.html" rel="external">
          "AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis", section on 'Epidemiology and risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3699.html" rel="external">
          "Cardiac and vascular disease in patients with HIV", section on 'Pericardial disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1385530920">
         <span class="h3">
          Primary pericardial tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary malignancies arising in the pericardium are extremely rare [
         <a href="#rid2">
          2
         </a>
         ]. These include mesotheliomas, teratomas, and paragangliomas. The differential diagnosis for these conditions includes benign lesions such as pericardial cysts and lipomas. These conditions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">
          "Cardiac tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3788523170">
         <span class="h2">
          Cancer therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cancer treatment, such as RT or antineoplastic agents, is frequently associated with pericardial disease in patients with cancer. In one observational study of patients undergoing pericardiocentesis for pericardial effusion, cancer therapy was identified as a likely etiology in almost 60 percent of patients with pericardial disease and cancer [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2621172855">
         <span class="h3">
          Radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT to the chest is a cause of acute pericarditis, with or without pericardial effusion. Patients may present days to weeks after initiating RT. RT less commonly causes constrictive pericarditis, which may manifest months to years after therapy is completed [
         <a href="#rid23">
          23,24
         </a>
         ]. Radiation-induced pericardial disease is most commonly caused by RT for Hodgkin lymphoma, breast, esophageal, or lung cancer. (See
         <a class="local">
          'Clinical presentation'
         </a>
         below.)
        </p>
        <p>
         The risk of radiation-induced pericarditis has declined with contemporary RT techniques [
         <a href="#rid24">
          24-27
         </a>
         ]. However, high rates of pericardial effusion have been reported in observational series of patients treated with RT for lung or esophageal cancer, although many of the pericardial effusions were asymptomatic [
         <a href="#rid28">
          28,29
         </a>
         ]. A systematic review found that symptomatic pericardial effusion typically occurs with cardiac RT doses greater than 40 Gy [
         <a href="#rid30">
          30
         </a>
         ]. Another study of patients with esophageal cancer found that pericarditis occurred only in patients who had received a dose of 3.5 Gy daily fraction; thus, a daily limit of 2 Gy daily fraction to the heart was suggested [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/111731.html" rel="external">
          "Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Pericarditis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">
          "Cardiotoxicity of radiation therapy for breast cancer and other malignancies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3995359411">
         <span class="h3">
          Cancer-directed therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antineoplastic agents that can cause pericarditis or pericardial effusion include cytotoxic chemotherapy (eg,
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         , anthracyclines,
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         , and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ), and other targeted agents (eg,
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          all-trans retinoic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">
          arsenic trioxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ) [
         <a href="#rid11">
          11,32-34
         </a>
         ]. Immune checkpoint inhibitors are a rare cause of acute pericarditis and pericardial effusion, which is often complicated by cardiac tamponade [
         <a href="#rid35">
          35-37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Cardiovascular toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2937695472">
         <span class="h2">
          Infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infectious etiologies (viral, bacterial, fungal) are relatively uncommon causes of pericardial diseases in patients with cancer (approximately 2 percent) [
         <a href="#rid15">
          15
         </a>
         ] However, infectious pericardial disease can be associated with high mortality in patients who are immunocompromised, especially when the etiology is fungal infection [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">
          "Etiology of pericardial disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2128.html" rel="external">
          "Purulent pericarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">
          "Tuberculous pericarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cancer, pericardial disease can present as acute pericarditis, pericardial effusion with or without cardiac tamponade, constrictive pericarditis, or effusive-constrictive pericarditis [
         <a href="#rid7">
          7,39-47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Acute pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute pericarditis can present with or without a pericardial effusion. It is unusual for malignant involvement of the pericardium to present with acute pericarditis without an associated pericardial effusion or pericardial mass.
        </p>
        <p>
         Among patients presenting with acute pericarditis or a small pericardial effusion without known cancer, the likelihood of identifying an undiagnosed cancer ranges between approximately 3 and 7 percent [
         <a href="#rid7">
          7,39-43
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         Acute pericarditis can present with a variety of nonspecific signs and symptoms, depending on the underlying etiology. Common clinical manifestations include pleuritic chest pain, fever, pericardial friction rub, and diffuse ST elevation and PR depression on the electrocardiogram (ECG)  (
         <a class="graphic graphic_waveform graphicRef77572" href="/z/d/graphic/77572.html" rel="external">
          waveform 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Further details on the diagnosis and treatment of acute pericarditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">
          "Acute pericarditis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Pericardial effusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with cancer commonly have pericardial effusions. Among patients with cancer and a pericardial effusion requiring drainage, approximately 50 percent will have a malignant effusion, although this percentage varies depending upon the type of cancer and exposures to other causes of pericardial effusion.
        </p>
        <p>
         Among patients without a known cancer, the likelihood of a malignant pericardial effusion is higher in the presence of moderate or large pericardial effusion than with a small pericardial effusion. In a series of 57 patients with a new large effusion, a specific diagnosis was established by pericardial biopsy and/or fluid cytology in 93 percent; 13 patients (23 percent) were newly diagnosed with cancer [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         Pericardial effusion may occur with or without associated pericarditis. The presence of pericardial effusion is generally confirmed by echocardiography, although additional cardiac imaging is required in selected cases. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         and
         <a class="local">
          'Further cardiac imaging'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2156027406">
         <span class="h3">
          With cardiac tamponade
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with malignant pericardial effusion develop cardiac tamponade. In cardiac tamponade, the pressure from the accumulating pericardial effusion approaches and then equalizes with intracardiac pressures, leading to impaired filling of one or both ventricles and decreased cardiac output. Cardiac tamponade may be caused by a circumferential or loculated pericardial effusion; the latter may be missed in standard parasternal and apical echocardiographic views. The clinical features, diagnosis, and management of cardiac tamponade are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p>
         Malignant pericardial effusion is a common cause of cardiac tamponade. This was illustrated in an observational study of 173 patients undergoing pericardiocentesis for hemodynamically significant pericardial effusion, among whom most (84 percent) were diagnosed with tamponade [
         <a href="#rid9">
          9
         </a>
         ]. The most common etiology was malignancy, which was diagnosed in 58 patients (33 percent). Among those 58 patients with malignant pericardial effusion, 45 patients had known malignant disease and 13 patients had newly diagnosed cancer. Tamponade with hemorrhagic pericardial effusion was more common in patients with malignant effusions than in those with other causes of pericardial disease.
        </p>
        <p>
         The clinical features of cardiac tamponade vary depending upon whether the onset of fluid accumulation is acute or subacute. In the setting of cancer, cardiac tamponade is most commonly subacute.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute cardiac tamponade
         </strong>
         – Acute cardiac tamponade is generally rapid in onset, may be associated with chest pain and dyspnea, and is life-threatening if not promptly treated. With rapid introduction of even a small amount of fluid into the pericardial space, the parietal pericardium cannot acutely stretch to accommodate the increase in volume. This results in an acute rise in pericardial pressure, which is transmitted to all cardiac chambers and limits diastolic filling. Common clinical findings include tachycardia, hypotension, narrow pulse pressure, jugular venous distention, and pulsus paradoxus (an accentuated inspiratory decrease in systolic blood pressure).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subacute cardiac tamponade
         </strong>
         – Subacute cardiac tamponade is a less dramatic process. Patients may be asymptomatic or complain of one or more of the following: fatigue, dyspnea, chest discomfort or fullness, and edema. Hypotension may or may not be present. Low pressure (occult) cardiac tamponade is a subset of subacute cardiac tamponade in which the patient is severely hypovolemic.
        </p>
        <p>
        </p>
        <p>
         A minority of patients with cardiac tamponade have effusive-constrictive pericarditis, as discussed below. (See
         <a class="local">
          'Effusive-constrictive pericarditis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23149625">
         <span class="h3">
          Without cardiac tamponade
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients without a hemodynamically significant pericardial effusion (ie, without cardiac tamponade) will have no symptoms specific to the effusion, but they may have symptoms related to the underlying cause (eg, fever in the setting of pericarditis). The pericardial effusion may be acute (recent onset), recurrent, or chronic. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Constrictive pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Constrictive pericarditis, sometimes referred to as pericardial constriction, generally results from scarring and fibrosis of the visceral and/or parietal pericardium, which progressively restricts diastolic filling of the ventricles. Patients with constrictive pericarditis typically present with one or both of the following constellations of symptoms: symptoms related to fluid overload, ranging from peripheral edema to anasarca; and/or symptoms related to diminished cardiac output in response to exertion, such as fatigability and dyspnea on exertion. (See
         <a class="medical medical_review" href="/z/d/html/140205.html" rel="external">
          "Constrictive pericarditis: Clinical features and causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
         Patients presenting with constrictive pericarditis have a low likelihood of harboring an undiagnosed malignancy. In observational studies of patients with constrictive pericarditis, malignancy was identified in fewer than 3 percent [
         <a href="#rid44">
          44-46
         </a>
         ]. Most cases of constrictive pericarditis in resource abundant countries are idiopathic, related to prior cardiac surgery, or caused by radiation; malignancy is an uncommon cause. Tuberculosis is a common cause of constrictive pericarditis in resource-limited countries.
        </p>
        <p>
         However, a significant percentage of patients with constrictive pericarditis have been previously treated with radiation therapy (RT) for malignancy; in observational series of patients with constrictive pericarditis, RT (most commonly used to treat Hodgkin lymphoma or breast cancer) was the suspected cause in 9 to 31 percent of patients [
         <a href="#rid44">
          44-46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1323007610">
         <span class="h2">
          Effusive-constrictive pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this condition, there is both a hemodynamically significant pericardial effusion and pericardial constriction. Drainage of pericardial fluid may unmask findings typical of constrictive physiology. Most cases of effusive-constrictive pericarditis are idiopathic; radiation and cancer are less common causes [
         <a href="#rid48">
          48,49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Effusive-constrictive pericarditis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSTIC EVALUATION FOR PERICARDIAL DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H322864906">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a known or suspected cancer and suspected pericardial disease, our approach is detailed below. (See
         <a class="local">
          'Initial evaluation'
         </a>
         below.)
        </p>
        <p>
         For patients without a known cancer, pericardial disease may be the first manifestation of malignancy. Patients who should undergo a detailed evaluation for occult cancer include those with persistent or recurrent pericarditis that is unresponsive to antiinflammatory therapy, those in whom cancer is suspected (eg, unexplained weight loss or a heavy smoking history), and those who present with a new large pericardial effusion or cardiac tamponade. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4878.html" rel="external">
          "Overview of the classification and management of cancers of unknown primary site"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2272810454">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected malignant pericardial disease are initially evaluated by history, physical examination, ECG, chest radiograph, and transthoracic echocardiogram.
        </p>
        <p class="headingAnchor" id="H1358464200">
         <span class="h3">
          Laboratory tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute pericarditis
         </strong>
         – In patients with suspected acute pericarditis, certain markers of inflammation (white blood cell count, erythrocyte sedimentation rate, and serum C-reactive protein) are often elevated, whether or not malignant pericardial disease is present. Further details on initial laboratory testing for acute pericarditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial effusion
         </strong>
         – The approach to initial laboratory testing for suspected pericardial effusion is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – The approach to initial laboratory testing for suspected constrictive pericarditis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Initial tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3096111025">
         <span class="h3">
          Electrocardiogram
         </span>
         <span class="headingEndMark">
          —
         </span>
         An ECG may show changes suggestive of pericardial disease, regardless of the etiology of disease. The ECG may also show atrial fibrillation, which is common in patients with pericardial disease, particularly those with constrictive pericarditis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute pericarditis
         </strong>
         – In patients with acute pericarditis, characteristic ECG findings include diffuse ST elevation (typically concave up) with reciprocal ST depression in leads aVR and V1  (
         <a class="graphic graphic_waveform graphicRef77572" href="/z/d/graphic/77572.html" rel="external">
          waveform 1
         </a>
         ). There is also frequently an atrial current of injury, reflected by elevation of the PR segment in lead aVR and depression of the PR segment in other limb leads and in the left chest leads, primarily V5 and V6. Thus, the PR and ST segments typically change in opposite directions. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis", section on 'Electrocardiogram'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial effusion
         </strong>
         – In patients with a pericardial effusion, especially if cardiac tamponade is present, QRS voltage may be decreased and, occasionally, electrical alternans is seen  (
         <a class="graphic graphic_waveform graphicRef72525" href="/z/d/graphic/72525.html" rel="external">
          waveform 2
         </a>
         ). This abnormality is characterized by a cyclic beat-to-beat shift in the QRS axis associated with mechanical swinging of the heart to-and-fro, usually in a large pericardial effusion. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'ECG findings'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – There are no diagnostic ECG findings for constrictive pericarditis or effusive-constrictive pericarditis. Further details on ECG findings for this condition are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Electrocardiogram'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3066436941">
         <span class="h3">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chest radiograph is a standard test in the evaluation of suspected pericardial disease, although it has limited sensitivity and specificity for detection of pericardial disease and causes of pericardial disease such as cancer.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute pericarditis
         </strong>
         – A chest radiograph is typically normal with acute pericarditis with no or small pericardial effusion. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis", section on 'Chest radiograph'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial effusion
         </strong>
         – A large pericardial effusion may manifest as an enlarged cardiac silhouette on chest radiograph. In patients with subacute cardiac tamponade, an enlarged cardiac silhouette with clear lung fields may be seen. However, an enlarged cardiac silhouette is not specific for pericardial effusion as it may also be caused by cardiomegaly. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'Chest radiograph'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A chest radiograph is also useful for detecting a concomitant pleural effusion. In a surgical series of 47 patients treated for symptomatic pericardial effusion, 41 (87 percent) had a concomitant pleural effusion and 20 (42 percent) of these were cytologically positive for cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef54772" href="/z/d/graphic/54772.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – Pericardial calcifications in the presence of typical symptoms are strongly suggestive of constrictive pericarditis, although most patients with constrictive pericarditis do not have pericardial calcification on chest radiograph. Pericardial calcification is identified in a minority of patients with constrictive pericarditis caused by radiation therapy (RT) [
         <a href="#rid51">
          51
         </a>
         ]. Although pericardial calcification is not generally associated with malignant pericardial disease, its presence does not exclude cancer [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Chest radiograph'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3759773509">
         <span class="h3">
          Echocardiogram
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected pericardial disease should have a transthoracic echocardiogram. Echocardiography is the primary imaging tool used to establish the presence and quantity of a pericardial effusion and to evaluate its hemodynamic impact, particularly the presence of cardiac tamponade or constrictive physiology. For patients not requiring immediate therapeutic intervention, echocardiography is also the primary means to monitor changes in hemodynamic status or effusion size. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'Cardiac imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">
          "Cardiac tamponade"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2439938396">
         <span class="h2">
          Additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for additional testing is determined by the results of the initial evaluation. Additional testing may include further cardiac imaging, cardiac catheterization to assess hemodynamics, and evaluation of pericardial fluid and pericardial tissue. (See
         <a class="local">
          'Cytology'
         </a>
         below and
         <a class="local">
          'Flow cytometry'
         </a>
         below and
         <a class="local">
          'Indications for obtaining a pericardial specimen'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac tamponade
         </strong>
         – If there are symptoms and signs of cardiac tamponade, echocardiography is generally diagnostic. However, further imaging may be required if the transthoracic echocardiogram is technically suboptimal or negative but a loculated pericardial effusion or pericardial hematoma is suspected. (See
         <a class="local">
          'Further cardiac imaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with cardiac tamponade require urgent pericardial drainage or evacuation with analysis of pericardial fluid. (See
         <a class="local">
          'Pericardial effusion'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial effusion without tamponade
         </strong>
         – If a pericardial effusion is identified, and there is no evidence of cardiac tamponade, pericardial fluid sampling or a pericardial biopsy may be helpful to document potential neoplastic disease involving the pericardium, particularly if there is no preexisting diagnosis of cancer. (See
         <a class="local">
          'Cytology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – If there are symptoms and signs of constrictive pericarditis, cardiovascular magnetic resonance imaging (CMR), cardiac computed tomography (CT), and/or right heart catheterization may be needed to confirm the diagnosis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H772210321">
         <span class="h3">
          Further cardiac imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac CT or CMR is obtained if initial testing, including echocardiography, is nondiagnostic, but pericardial disease is still suspected [
         <a href="#rid53">
          53
         </a>
         ]. Indications include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loculated or hemorrhagic pericardial effusion
         </strong>
         – While a transthoracic echocardiogram is generally sufficient to identify most pericardial effusions, CMR or cardiac CT is indicated if the echocardiogram is technically suboptimal or negative but a loculated and/or hemorrhagic pericardial effusion is suspected [
         <a href="#rid54">
          54
         </a>
         ]. Both cardiac CT and CMR are helpful in identifying pericardial effusions and chamber collapse seen with cardiac tamponade  (
         <a class="graphic graphic_diagnosticimage graphicRef97074" href="/z/d/graphic/97074.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'Cardiac imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These modalities also have the advantage of providing information about the remainder of the chest as well (eg, detecting the presence of a primary tumor or metastatic foci within lung parenchyma). In some cases (particularly in the setting of trauma), a hematoma may be mistaken for a neoplasm. (See
         <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">
          "Clinical utility of cardiovascular magnetic resonance imaging", section on 'Pericardial disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – For patients with suspected constrictive pericarditis with nondiagnostic echocardiography, CMR or cardiac CT may be helpful as these modalities provide more accurate measures of pericardial thickness  (
         <a class="graphic graphic_diagnosticimage graphicRef61127" href="/z/d/graphic/61127.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef81292" href="/z/d/graphic/81292.html" rel="external">
          image 4
         </a>
         ) and may also identify other features of pericardial constriction  (
         <a class="graphic graphic_algorithm graphicRef141074" href="/z/d/graphic/141074.html" rel="external">
          algorithm 1
         </a>
         ). Increased pericardial thickness (&gt;2 mm) is suggestive of but not diagnostic for constrictive pericarditis. However, absence of pericardial thickening does not exclude constrictive pericarditis. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Cardiac CT or CMR'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diffuse, late pericardial gadolinium enhancement on CMR is a sign of pericarditis with active inflammation; less commonly, it is a sign of diffuse neoplastic involvement [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial mass
         </strong>
         – When a pericardial mass is suspected, cardiac CT  (
         <a class="graphic graphic_diagnosticimage graphicRef97072" href="/z/d/graphic/97072.html" rel="external">
          image 5
         </a>
         ) or CMR provide greater field of view and anatomic information than echocardiography, including identification of nodal and other extracardiac involvement. Additionally, cross-sectional imaging is frequently a part of the staging/restaging process of the cancer. Both abdominal and chest CT can provide information about the pericardial space  (
         <a class="graphic graphic_diagnosticimage graphicRef97073" href="/z/d/graphic/97073.html" rel="external">
          image 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Patients with a confirmed diagnosis of cancer may also require further systemic imaging for staging or restaging evaluation.
        </p>
        <p class="headingAnchor" id="H3786056563">
         <span class="h3">
          Cardiac catheterization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac catheterization may be obtained if testing, including echocardiography and other cardiac imaging, is inconclusive or equivocal for identifying cardiac tamponade or constrictive physiology (constrictive pericarditis versus restrictive cardiomyopathy). Cardiac catheterization is also used to monitor intracardiac pressures during pericardiocentesis. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
         Constrictive pericarditis is often difficult to distinguish from restrictive cardiomyopathy based upon clinical and echocardiographic criteria alone. Patients with prior chest radiation may develop constrictive pericarditis and/or restrictive cardiomyopathy. Cardiac catheterization can be used to distinguish between these two conditions using hemodynamic assessment with simultaneous right and left heart pressure measurement, particularly examination of respirophasic changes in pressures, to characterize the impact of pericardial disease upon cardiac filling and performance [
         <a href="#rid56">
          56
         </a>
         ]. Of note, RT can cause constrictive pericarditis and/or restrictive cardiomyopathy.
        </p>
        <p>
         Further details on the use of cardiac catheterization in this setting are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4946.html" rel="external">
          "Differentiating constrictive pericarditis and restrictive cardiomyopathy", section on 'Cardiac catheterization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1309587434">
         <span class="h1">
          DIAGNOSIS OF MALIGNANT PERICARDIAL DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of malignant pericardial disease is typically confirmed on pathology, using either cytology (with or without flow cytometry) of the pericardial fluid or pericardial tissue biopsy.
        </p>
        <p class="headingAnchor" id="H1274594646">
         <span class="h2">
          Pericardial effusion
         </span>
        </p>
        <p class="headingAnchor" id="H512805493">
         <span class="h3">
          Cytology
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with pericardial effusion of uncertain etiology who have undergone pericardial fluid sampling, cytologic examination is an initial step in identifying a malignant cause. Hemorrhagic effusions are more likely to be malignant than nonhemorrhagic effusions. Therefore, cytologic evaluation is especially important if the effusion is hemorrhagic and there is no history of antecedent trauma [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis"
         </a>
         .)
        </p>
        <p>
         The sensitivity of cytology for the diagnosis of a malignant effusion is between 67 and 92 percent and is lowest for mesothelioma and lymphoma [
         <a href="#rid12">
          12,14,58-60
         </a>
         ]. Immunohistochemical staining may help distinguish malignant cells from atypical mesothelial cells as well as identify the likely tissue of origin if malignant cells are present [
         <a href="#rid61">
          61-64
         </a>
         ].
        </p>
        <p>
         A positive cytology may be predictive of a poorer outcome in patients with neoplastic pericardial disease. In an observational study of patients with cancer-related pericardial effusion, positive cytology was associated with decreased overall survival (median 7 versus 30 weeks for normal cytology) [
         <a href="#rid13">
          13
         </a>
         ]. Patients with positive cytology were also more likely to require repeat pericardiocentesis or surgical intervention. (See
         <a class="medical medical_review" href="/z/d/html/141940.html" rel="external">
          "Pericardial disease associated with cancer: Management", section on 'Prevention and treatment of recurrent malignant pericardial effusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2445724086">
         <span class="h3">
          Flow cytometry
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a suspected hematologic malignancy, such as leukemia or lymphoma, flow cytometry of the pericardial fluid is an important adjunct to cytology [
         <a href="#rid65">
          65,66
         </a>
         ]. In an observational study of 115 serous cavity effusions from patients with a variety of malignant diagnoses, the provisional cytopathologic diagnosis was altered by the results of flow cytometry in 18 cases (16 percent of the total). Among those 18 cases, the diagnosis changed from atypical/suspicious to benign in eight cases and from benign or atypical/suspicious to malignant in 10 cases [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">
          "Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Pleural/pericardial fluid'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2322925168">
         <span class="h3">
          Indications for obtaining a pericardial specimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with negative cytology on pericardial effusion but for whom cancer is still highly suspected, we obtain a pericardial specimen for pathologic examination, since negative cytology does not exclude the diagnosis of cancer [
         <a href="#rid67">
          67
         </a>
         ]. The pericardial specimen may be obtained using the following methods:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial window
         </strong>
         – For patients who receive a pericardial window to facilitate drainage of pericardial fluid, the therapeutic drainage window created by a subxiphoid or transthoracic approach generally yields a &gt;4 cm
         <sup>
          2
         </sup>
         piece of tissue [
         <a href="#rid68">
          68,69
         </a>
         ], which can be useful to confirm the diagnosis. The subxiphoid approach provides more limited exposure with resected pericardial specimens typically 2 to 4 cm in width and length. A transthoracic approach provides access to a larger region of pericardium (particularly on the left side where windows both anterior and posterior to the phrenic nerve can be created) enabling more reliable long-term drainage and a larger tissue specimen for analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial biopsy
         </strong>
         – For patients not receiving a pericardial window, a pericardial biopsy can be performed via a subxiphoid or transthoracic pericardiostomy (window). Pericardial specimens are generally at least 2 cm x 2 cm to enable adequate pericardial fluid drainage and a sufficient tissue specimen for pathologic analysis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2347436940">
         <span class="h2">
          Constrictive pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with constrictive pericarditis are unlikely to have undiagnosed cancer, as most are related to prior radiation therapy (RT). Pericardial cancer involvement is a rare cause of constrictive pericarditis that may be diagnosed by pathologic examination of pericardial biopsy or pericardiectomy specimens. (See
         <a class="local">
          'Constrictive pericarditis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2306427144">
         <span class="h2">
          Acute pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with cancer, causes of acute pericarditis include cancer-directed therapy (RT or antineoplastic agents such as immune checkpoint inhibitors), infection, and malignancy, as well as other causes of pericardial disease  (
         <a class="graphic graphic_table graphicRef67851" href="/z/d/graphic/67851.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">
          "Etiology of pericardial disease"
         </a>
         .)
        </p>
        <p>
         For those with acute pericarditis and an associated significant pericardial effusion, pericardiocentesis can be performed and pericardial fluid removed for both diagnostic (ie, to distinguish malignancy from other causes) and therapeutic purposes. (See
         <a class="local">
          'Pericardial effusion'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis", section on 'Pericardiocentesis and pericardial biopsy'
         </a>
         .)
        </p>
        <p>
         For patients with suspected cancer who present with acute pericarditis alone (without effusion or mass), we do not routinely perform pericardial tissue sampling to diagnose cancer. It is extremely rare for malignancy to cause acute pericarditis without an associated pericardial effusion or mass, so the risks of this invasive procedure should be weighed against the likelihood of diagnosing malignancy. If cancer is still suspected after nondiagnostic or negative echocardiography, CT or CMR can be used to evaluate for potential signs of malignant pericardial involvement such as a loculated or hemorrhagic pericardial effusion or a pericardial or cardiac mass. (See
         <a class="local">
          'Further cardiac imaging'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1037242490">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">
          "Society guideline links: Pericardial disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1245187776">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3427.html" rel="external">
          "Patient education: Pericarditis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H971738">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Epidemiology
         </strong>
         – Pericardial disease occurs in approximately 10 to 20 percent of patients with cancer. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Causes
         </strong>
         – Clinical conditions that cause pericardial disease in patients with cancer include malignancy, cancer therapy (eg, radiation therapy [RT], antineoplastic agents), and infection. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Associated
         </strong>
         <strong>
          cancers
         </strong>
         – Among patients with cancer and pericardial effusion, the frequency of a malignant effusion is approximately 40 to 60 percent. Lung cancer is the most common malignancy to involve the pericardium. Other common cancers include breast, esophagus, melanoma, lymphoma, and leukemia. (See
         <a class="local">
          'Malignancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – In patients with cancer, pericardial disease can present as acute pericarditis, pericardial effusion with or without cardiac tamponade, constrictive pericarditis, or effusive-constrictive pericarditis. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect malignant pericardial disease in patients without previously known cancer
         </strong>
         – Patients who should undergo a detailed evaluation for occult cancer include those with persistent or recurrent pericarditis that is unresponsive to antiinflammatory therapy, those in whom cancer is suspected (eg, unexplained weight loss or a heavy smoking history), and those who present with a new large pericardial effusion or cardiac tamponade. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation for pericardial disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial evaluation
         </strong>
         – Patients with suspected malignant pericardial disease are initially evaluated by history, physical examination, ECG, chest radiograph, and transthoracic echocardiogram. (See
         <a class="local">
          'Initial evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory testing
         </strong>
         – In patients with suspected acute pericarditis, certain markers of inflammation (white blood cell count, erythrocyte sedimentation rate, and serum C-reactive protein) are often elevated, whether or not malignant pericardial disease is present. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis", section on 'Our approach to diagnostic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The approach to laboratory testing for suspected pericardial effusion and constrictive pericarditis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation", section on 'Initial tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">
          "Pericardial effusion: Approach to diagnosis", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Further cardiac imaging
         </strong>
         – Cardiac computed tomography (CT) or cardiovascular magnetic resonance imaging (CMR) is obtained if initial testing, including echocardiography, is nondiagnostic, but pericardial disease is still suspected. Indications include a loculated or hemorrhagic pericardial effusion, constrictive pericarditis, or a pericardial mass. (See
         <a class="local">
          'Further cardiac imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardiac catheterization
         </strong>
         – Cardiac catheterization may be obtained if initial testing, including echocardiography, is inconclusive or equivocal for identifying cardiac tamponade or constrictive physiology (constrictive pericarditis versus restrictive cardiomyopathy). Cardiac catheterization is also used to monitor intracardiac pressures during pericardiocentesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of malignant pericardial disease
         </strong>
         – The diagnosis of malignant pericardial disease is typically confirmed on pathology.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pericardial effusion
         </strong>
         – In patients with pericardial effusion of uncertain etiology who have undergone pericardial fluid sampling, cytologic examination is an initial step in identifying a malignant cause. Flow cytometry is an important adjunct to cytology for patients with a suspected leukemia or lymphoma. (See
         <a class="local">
          'Cytology'
         </a>
         above and
         <a class="local">
          'Flow cytometry'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with negative cytology but for whom cancer is still highly suspected, we obtain a pericardial specimen for pathologic examination since negative cytology does not exclude the diagnosis of cancer. The pericardial specimen may be obtained during the creation of a pericardial window or through pericardial biopsy. (See
         <a class="local">
          'Indications for obtaining a pericardial specimen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Constrictive pericarditis
         </strong>
         – For the rare patient with constrictive pericarditis where cancer is the suspected etiology despite a thorough initial evaluation, the diagnosis is confirmed by pathologic examination of pericardial tissue. (See
         <a class="local">
          'Constrictive pericarditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute pericarditis
         </strong>
         - For patients with acute pericarditis and an associated significant pericardial effusion, pericardiocentesis can be performed and pericardial fluid removed for both diagnostic (to distinguish malignancy from other causes) and therapeutic purposes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with acute pericarditis alone (without pericardial effusion), we do not routinely perform pericardial tissue sampling to diagnose cancer. If cancer is still suspected after nondiagnostic or negative echocardiography, CT or CMR can be obtained to evaluate for potential signs of malignant pericardial involvement such as a loculated or hemorrhagic pericardial effusion, or a pericardial or cardiac mass. (See
         <a class="local">
          'Acute pericarditis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2892451230">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Howard (Jack) West, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010; 53:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993; 117:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klatt EC, Heitz DR. Cardiac metastases. Cancer 1990; 65:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham KP, Reddy V, Gattuso P. Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990; 3:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nova-Camacho LM, Gomez-Dorronsoro M, Guarch R, et al. Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study. Arch Pathol Lab Med 2023; 147:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGee W. Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study. Virchows Arch A Pathol Anat Histopathol 1991; 419:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Søgaard KK, Sørensen HT, Smeeth L, Bhaskaran K. Acute Pericarditis and Cancer Risk: A Matched Cohort Study Using Linked UK Primary and Secondary Care Data. J Am Heart Assoc 2018; 7:e009428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart 2020; 106:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Horin S, Bank I, Guetta V, Livneh A. Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. Medicine (Baltimore) 2006; 85:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pãosinho A, Esteves AL, Pereira AJ. From the Gut to the Heart: Cardiac Tamponade due to Lymphatic Metastasis. Eur J Case Rep Intern Med 2019; 6:001033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43:4229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005; 23:5211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porte HL, Janecki-Delebecq TJ, Finzi L, et al. Pericardoscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 1999; 16:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Haddad D, Iliescu C, Yusuf SW, et al. Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol 2015; 66:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter D, Jadoon M, McGrogan D, Nzewi O. Occult malignancy presenting as constrictive pericarditis. Interact Cardiovasc Thorac Surg 2011; 12:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012; 118:4502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampat K, Rossi A, Garcia-Gutierrez V, et al. Characteristics of pericardial effusions in patients with leukemia. Cancer 2010; 116:2366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaric D, Holley D, Lau KC, McCowage G. It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis. Leuk Lymphoma 2002; 43:2417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savoia P, Fierro MT, Zaccagna A, Bernengo MG. Metastatic melanoma of the heart. J Surg Oncol 2000; 75:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Brennessel D, Walters J, et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gouny P, Lancelin C, Girard PM, et al. Pericardial effusion and AIDS: benefits of surgical drainage. Eur J Cardiothorac Surg 1998; 13:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ning MS, Tang L, Gomez DR, et al. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017; 99:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintero-Martinez JA, Cordova-Madera SN, Villarraga HR. Radiation-Induced Heart Disease. J Clin Med 2021; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev 2012; 20:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szpakowski N, Desai MY. Radiation-Associated Pericardial Disease. Curr Cardiol Rep 2019; 21:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beukema JC, Kawaguchi Y, Sijtsema NM, et al. Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients? Radiother Oncol 2020; 149:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cella L, Monti S, Xu T, et al. Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. Radiother Oncol 2021; 160:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niska JR, Thorpe CS, Allen SM, et al. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Expert Rev Cardiovasc Ther 2018; 16:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martel MK, Sahijdak WM, Ten Haken RK, et al. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys 1998; 40:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogan SE, Mizrak D, Alkan A, Demirkazik A. Docetaxel-induced pericardial effusion. J Oncol Pharm Pract 2017; 23:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol 2017; 70:2552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskazan AE, Soysal T, Ongoren S, et al. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica 2011; 96:e15; author reply e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation 2017; 136:2085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016; 4:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inno A, Maurea N, Metro G, et al. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunol Immunother 2021; 70:3041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Mouhayar E, Tarrand JJ, Kontoyiannis DP. Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. Mycoses 2018; 61:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imazio M, Demichelis B, Parrini I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol 2005; 95:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Permanyer-Miralda G, Sagristá-Sauleda J, Soler-Soler J. Primary acute pericardial disease: a prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Søgaard KK, Farkas DK, Ehrenstein V, et al. Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality. Circulation 2017; 136:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron J, Oesterle SN, Baldwin JC, Hancock EW. The etiologic spectrum of constrictive pericarditis. Am Heart J 1987; 113:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 1999; 100:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 2004; 43:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corey GR, Campbell PT, Van Trigt P, et al. Etiology of large pericardial effusions. Am J Med 1993; 95:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann T, Brodie BR, Grossman W, McLaurin L. Effusive-constrictive hemodynamic pattern due to neoplastic involvement of the pericardium. Am J Cardiol 1978; 41:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda WR, Oh JK. Effusive-Constrictive Pericarditis. Cardiol Clin 2017; 35:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross JL, Younes RN, Deheinzelin D, et al. Surgical management of symptomatic pericardial effusion in patients with solid malignancies. Ann Surg Oncol 2006; 13:1732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling LH, Oh JK, Breen JF, et al. Calcific constrictive pericarditis: is it still with us? Ann Intern Med 2000; 132:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Liu D, Zhang D, et al. Primary pericardial mesothelioma complicated by pericardial calcification. BMC Cardiovasc Disord 2023; 23:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang ZJ, Reddy GP, Gotway MB, et al. CT and MR imaging of pericardial disease. Radiographics 2003; 23 Spec No:S167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellon RJ, Wright WH, Unger EC. CT-guided pericardial drainage catheter placement with subsequent pericardial sclerosis. J Comput Assist Tomogr 1995; 19:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montes Muñiz Á, Cecconi A, Freih A, et al. Pericardial late gadolinium enhancement secondary to metastatic recurrence in long-term survivor of breast cancer. Eur Heart J Cardiovasc Imaging 2021; 22:e141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurrell DG, Nishimura RA, Higano ST, et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation 1996; 93:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s? Chest 1999; 116:1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiener HG, Kristensen IB, Haubek A, et al. The diagnostic value of pericardial cytology. An analysis of 95 cases. Acta Cytol 1991; 35:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. Chest 1997; 111:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saab J, Hoda RS, Narula N, et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathol 2017; 125:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoppi JA, Pellicer EM, Sundblad AS. Diagnostic value of p53 protein in the study of serous effusions. Acta Cytol 1995; 39:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong Y, Sun X, Michael CW, et al. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol 2003; 28:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayall F, Heryet A, Manga D, Kriegeskotten A. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology. Cytopathology 1997; 8:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iqbal J, Liu T, Mapow B, et al. Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol 2010; 32:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czader M, Ali SZ. Flow cytometry as an adjunct to cytomorphologic analysis of serous effusions. Diagn Cytopathol 2003; 29:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardales RH, Stanley MW, Schaefer RF, et al. Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis. Am J Clin Pathol 1996; 106:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontenelle LJ, Cuello L, Dooley BN. Subxiphoid pericardial window. A simple and safe method for diagnosing and treating acute and chronic pericardial effusions. J Thorac Cardiovasc Surg 1971; 62:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langdon SE, Seery K, Kulik A. Contemporary outcomes after pericardial window surgery: impact of operative technique. J Cardiothorac Surg 2016; 11:73.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4954 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20728703" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evaluation and management of pericardial effusion in patients with neoplastic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8215825" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2306690" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cardiac metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2095826" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neoplasms metastatic to the heart: review of 3314 consecutive autopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35639589" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1926759" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30369322" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute Pericarditis and Cancer Risk: A Matched Cohort Study Using Linked UK Primary and Secondary Care Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31980441" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16523053" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30931268" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : From the Gut to the Heart: Cardiac Tamponade due to Lymphatic Metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36017568" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8620412" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051963" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10554845" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pericardoscopy for primary management of pericardial effusion in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26337990" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422161" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Occult malignancy presenting as constrictive pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22282022" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20209609" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Characteristics of pericardial effusions in patients with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12613535" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : It is ALL in the heart: a patient with acute lymphoblastic leukemia and cardiac infiltration at time of diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11088053" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Metastatic melanoma of the heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10047635" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9583822" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pericardial effusion and AIDS: benefits of surgical drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28816165" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35011887" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Radiation-Induced Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23583253" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cardiac complications of thoracic irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22314140" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Radiation-induced heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31352541" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Radiation-Associated Pericardial Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32445862" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33979653" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30360659" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Radiation and the heart: systematic review of dosimetry and cardiac endpoints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9422572" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fraction size and dose parameters related to the incidence of pericardial effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27105899" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Docetaxel-induced pericardial effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29145955" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21357709" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29158217" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27532025" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33877385" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280197" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: Case report and review of fungal pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904655" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Relation of acute pericardial disease to malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4050698" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Primary acute pericardial disease: a prospective series of 231 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7856532" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17502574" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Indicators of poor prognosis of acute pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28663234" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3812191" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The etiologic spectrum of constrictive pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10500037" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15093882" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8356985" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Etiology of large pericardial effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/645585" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effusive-constrictive hemodynamic pattern due to neoplastic involvement of the pericardium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025546" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effusive-Constrictive Pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17028771" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Surgical management of symptomatic pericardial effusion in patients with solid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733443" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Calcific constrictive pericarditis: is it still with us?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36890475" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Primary pericardial mesothelioma complicated by pericardial calcification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557510" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : CT and MR imaging of pericardial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7622713" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : CT-guided pericardial drainage catheter placement with subsequent pericardial sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33755095" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pericardial late gadolinium enhancement secondary to metastatic recurrence in long-term survivor of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640975" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10593777" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2028688" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The diagnostic value of pericardial cytology. An analysis of 95 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9149572" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The usefulness of diagnostic tests on pericardial fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28207201" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7631546" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Diagnostic value of p53 protein in the study of serous effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12508174" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9068950" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20701070" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12889043" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Flow cytometry as an adjunct to cytomorphologic analysis of serous effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8701928" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Secondary pericardial malignancies: a critical appraisal of the role of cytology, pericardial biopsy, and DNA ploidy analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5091692" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Subxiphoid pericardial window. A simple and safe method for diagnosing and treating acute and chronic pericardial effusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27118051" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Contemporary outcomes after pericardial window surgery: impact of operative technique.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
